This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Rebecca Voelker

JAMA. 1999;281:889.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

After 8 years of planning, the first clinical trial of an HIV vaccine in Africa has been launched in Uganda.

The trial is being conducted at the Joint Clinical Research Center in Kampala and at the Uganda Virus Research Institute in Entebbe. It will evaluate the safety and durability of immune response to a vaccine known as ALVAC vCP205, which is based on an attenuated canarypox virus. The vaccine contains only three HIV genes, rendering it incapable of causing HIV infection.

Researchers involved in phase 1 of the double-blind trial are enrolling 40 healthy, HIV-negative adults aged 18 to 40 years who are at low risk of becoming HIV infected. They will be assigned randomly to a group of 20 who will receive the HIV vaccine, 10 serving as controls by receiving an experimental canarypox vaccine for rabies, or 10 who will receive a placebo injection.

Each trial . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?